Press Release

SAN FRANCISCO, March 1, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced five data presentations will be delivered at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which will be held April 1-5, 2017 at the Walter E. Washington Convention Center in Washington, D.C. Researchers will present new preclinical data on NKTR-214, the Company's immuno-stimulatory CD122-biased agonist, as well as on NKTR-255, the Company's IL-15 therapeutic candidate.

Details of the poster presentations are as follows:
Abstract 1598/Poster 6: "Single agent NKTR-214, a biased IL2 pathway agonist, increases immune cell infiltrates in brain tumors and prolongs survival in rodent (rattus) glioblastoma (GBM)"
Session: Cytokines: The First Modern Immunotherapies
Date and Time: Monday, April 3, 2017, 8:00 AM - 12:00 PM Eastern Time
Location: Convention Center, Halls A-C, Poster Section 26

Abstract 1603/Poster 11: "NKTR-255 engages the IL-15 pathway driving CD8 T cell survival and CD8 memory T cell proliferation"
Session: Cytokines: The First Modern Immunotherapies
Date and Time: Monday, April 3, 2017, 8:00 AM - 12:00 PM Eastern Time
Location: Convention Center, Halls A-C, Poster Section 26

Abstract 1604/Poster 12: "NKTR-214 Synergizes with Radiotherapy to Drive Tumor Regression"
Session: Cytokines: The First Modern Immunotherapies
Date and Time: Monday, April 3, 2017, 8:00 AM - 12:00 PM Eastern Time
Location: Convention Center, Halls A-C, Poster Section 26

Abstract 1617/Poster 25: "Mechanistic modeling of a new kinetically-controlled CD122 agonist for cancer immunotherapy: NKTR-214 pharmacokinetics, pharmacodynamics, and receptor pharmacology"
Session: Cytokines: The First Modern Immunotherapies
Date and Time: Monday, April 3, 2017, 8:00 AM - 12:00 PM Eastern Time
Location: Convention Center, Halls A-C, Poster Section 26

Abstract 2671/Poster 30: "Antitumor activity of NKTR-214 in combination with Adopted Cell Transfer (ACT) in an aggressive murine melanoma"
Session: Immune Response to Hematopoietic Tumors: New Development in Tumor Immunology
Date and Time: Monday, April 3, 20171:00 PM - 5:00 PM Eastern Time
Location: Convention Center, Halls A-C, Poster Section 26

About Nektar Therapeutics

Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact:

For Investors:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585

Jodi Sievers of Nektar Therapeutics
415-482-5593

For Media:
Dan Budwick of Pure Communications
973-271-6085
dan@purecommunications.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-announces-upcoming-presentations-at-the-american-association-for-cancer-research-annual-meeting-300416349.html

SOURCE Nektar Therapeutics